Presentation,
22nd annual San Antonio Breast Cancer Symposium
(Source:
Breast Cancer Update for Surgeons, Program 1 2000)
Play
Audio Below:
Again,
data from the P-1 trial, looking at a population of 1,100 patients
with atypical hyperplasia, shows that you reduce the relative risk
of breast cancer development by about 85 percent with the administration
of tamoxifen for five years; benefits in lobular carcinoma in situ,
slightly less, but, again, significant. So, for the high-risk patient,
this is an excellent treatment option and certainly a less morbid
alternative to prophylactic mastectomy. But like ductal carcinoma
in situ, the problem with atypical hyperplasia remains that what
we really need are predictors based on changes in individual lesions
that will tell us which lesions have the potential to progress to
invasive carcinoma.
Chemoprevention
of breast cancer [Review]. Brown, P. H. and Lippman, S. M. (Reprint available from: Lippman
SM Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent 1515
Holcombe Blvd,Box 236 Houston, TX 77030 USA). Breast Cancer Research
& Treatment. 62(1):1-17, 2000 Jul.
Vitamin
A analogue for breast cancer prevention: a grade of F or incomplete?
Response Piantadosi, S. (Reprint available from: Piantadosi S Johns Hopkins
Univ, Sch Med, Johns Hopkins Oncol Ctr 550 N Broadway,Suite 1103
Baltimore, MD 21205 USA).. Journal of the National Cancer Institute.
92(3):274-275, 2000 Feb 2. No abstract
Tamoxifen
for the prevention of breast cancer in the high-risk woman.
Morrow, M. and Jordan, V. C. (Reprint available from: Morrow M 676
N St Clair St,13th Floor, Room 13-104 Chicago, IL 60611 USA).. Annals
of Surgical Oncology. 7(1):67-71, 2000 Jan-Feb. No abstract
